Journal of Neurology

, 254:1233 | Cite as

Revised diagnostic criteria for neuromyelitis optica (NMO)

Application in a series of suspected patients
  • Albert Saiz
  • Luigi Zuliani
  • Yolanda Blanco
  • Bruno Tavolato
  • Bruno Giometto
  • Francesc Graus
  • for the Spanish–Italian NMO study group


We analyzed neuromyelitis optica (NMO) IgG in the serum or CSF samples from 46 patients with suspected NMO (28) and limited forms of NMO (18). One hundred and fifteen samples from multiple sclerosis (MS) patients were included as controls. The final clinical diagnosis after follow-up was 16 NMO, 12 MS, 11 transverse myelitis (TM) and seven recurrent optic neuritis (RON). NMO-IgG was detected in 62.5% of NMO, 50% of the recurrent longitudinally extensive TM, 14.3% of the RON but in none of the MS patients. The authors then compared the newly revised diagnostic criteria for NMO with the criteria published in 1999, in the 28 patients with suspected NMO. The revised criteria had higher specificity, and positive and negative predictive value (83.3% vs. 25%; 87.5% vs. 62.5; 83.3% vs. 75%), but slightly lower sensitivity (87.5% vs. 93.7%). Our study confirms NMO-IgG as a highly specific marker of NMO, and the usefulness of the revised diagnostic criteria in predicting a diagnosis of NMO.

Key words

neuromyelitis optica multiple sclerosis Devic’s syndrome NMO-IgG antibody transverse myelitis optic neuritis 


  1. 1.
    Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuck D, Parisi JE, Lassmann H (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125:1450–1461CrossRefPubMedGoogle Scholar
  2. 2.
    Mandler RN, Davis LE, Jeffery DR, Kornfeld M (1993) Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 34:162–168CrossRefPubMedGoogle Scholar
  3. 3.
    O’Riordan JL, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EJ, McDonald WI, Miller DH (1996) Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry 60:382–387CrossRefPubMedGoogle Scholar
  4. 4.
    Wingerchuck DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53:1107–1114Google Scholar
  5. 5.
    Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477CrossRefPubMedGoogle Scholar
  6. 6.
    Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112CrossRefPubMedGoogle Scholar
  7. 7.
    Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59:566–569CrossRefPubMedGoogle Scholar
  8. 8.
    Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489CrossRefPubMedGoogle Scholar
  9. 9.
    Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GS, Johnson KP, Sibley WA, Silberger DM, Tourtellote WW (1983) New diagnostic criteria for multiple sclerosis; guidelines for research protocols. Ann Neurol 13:227–231CrossRefPubMedGoogle Scholar
  10. 10.
    Saiz A, Arpa J, Sagasta A, Casamitjana R, Zarranz JJ, Tolosa E, Graus F (1997) Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulindependent diabetes mellitus, and polyendocrine autoimmunity. Neurology 49:1026–1030PubMedGoogle Scholar
  11. 11.
    Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, Dalmau J (2005) Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 165:s166–171CrossRefGoogle Scholar
  12. 12.
    Zuliani L, López de Munain A, Ruiz Martínez J, Olascoaga J, Graus F, Saiz A (2006) Anticuerpos IgG-NMO en la neuromielitis óptica: a propósito de 2 casos. Neurología 6:314–317Google Scholar
  13. 13.
    Ghezzi A, Bergamaschi R, Martinelli V, Trojano M, Tola MR, Merelli E, Mancardi L, Gallo P, Filippi M, Zaffaroni M, Comi G, the Italian Devic’s study group (IDESG) (2004) Clinical characteristics, course and prognosis of relapsing Devic’s neuromyelitis optica. J Neurol 251:47–52CrossRefPubMedGoogle Scholar
  14. 14.
    Blanche P, Diaz E, Gombert B, Sicard D (2000) Devic’s neuromyelitis optica and HIV-1 infection. J Neurol Neurosurg Psychiatry 68:795–796CrossRefPubMedGoogle Scholar
  15. 15.
    Durán E, Gálvez J, Patriagnani G, Izquierdo G (2004) Multiple sclerosis-like illnes in a HIV-1 patient. J Neurol 251:1142–1144CrossRefPubMedGoogle Scholar
  16. 16.
    Lalive PH, Menge T, Barman I, Cree BA, Genain CP (2006) Identification of new serum autoantibodies in neuromyleitis optica using protein microarrays. Neurology 67:176–177CrossRefPubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2007

Authors and Affiliations

  • Albert Saiz
    • 1
  • Luigi Zuliani
    • 2
  • Yolanda Blanco
    • 1
  • Bruno Tavolato
    • 2
  • Bruno Giometto
    • 3
  • Francesc Graus
    • 1
  • for the Spanish–Italian NMO study group
  1. 1.Service of Neurology, Hospital Clinic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS)University of BarcelonaBarcelonaSpain
  2. 2.Dept. of NeuroscienceHospital of PaduaPaduaItaly
  3. 3.Dept. of NeurologyHospital of TrevisoTrevisoItaly

Personalised recommendations